F1_RD

C Number:	C20515
Lock Date:	04/04/2007
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.0.0

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Metal working fluids (CIMSTAR 3800)

MALE RATS

Organ	Morphology
Larynx	Inflammation Chronic
	Metaplasia
Larynx: Squamous Epithelium	Hyperplasia
Liver	Hepatodiaphragmatic Nodule
Lung: Alveolus	Infiltration Cellular Histiocyte
Nose: Goblet Cell	Hyperplasia
Nose: Olfactory Epithelium	Accumulation, Hyaline Droplet
	Inflammation
Nose: Respiratory Epithelium	Accumulation, Hyaline Droplet
	Inflammation

FEMALE RATS

Organ	Morphology
Larynx	Inflammation Chronic
	Metaplasia
Larynx: Squamous Epithelium	Hyperplasia
Liver	Hepatodiaphragmatic Nodule
	Inflammation Granulomatous
Lung: Alveolus	Infiltration Cellular Histiocyte
Nose: Goblet Cell	Hyperplasia
Nose: Olfactory Epithelium	Accumulation, Hyaline Droplet
	Inflammation
Nose: Respiratory Epithelium	Accumulation, Hyaline Droplet
	Inflammation
Ovary	Cyst

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Heart **Cardiomyopathy**						
LESION RATES						
OVERALL (a)	6/10 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
POLY-3 RATE (b)	6/10.00	0/0.00	0/0.00	0/0.00	0/0.00	6/10.00
POLY-3 PERCENT (g)	60%	0%	0%	0%	0%	60%
TERMINAL (d)	6/10 (60%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.667
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.667
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.667
COCH-ARM / FISHERS	P=0.590	(e)	(e)	(e)	(e)	P=0.675N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Kidney **Nephropathy**						
LESION RATES						
OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	7/10 (70%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	7/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	70%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	7/10 (70%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.292N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.292N
COCH-ARM / FISHERS	P=0.201N	(e)	(e)	(e)	(e)	P=0.291N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.136N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Larynx						
Inflammation Chronic						
LESION RATES						
OVERALL (a)	1/10 (10%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	1/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	10%	90%	100%	100%	100%	100%
TERMINAL (d)	1/10 (10%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Larynx **Metaplasia**						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Larynx: Squamous Epithelium Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	6/10.00	5/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	60%	50%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	6/10 (60%)	5/10 (50%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P=0.008**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P=0.008**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P=0.008**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.005**	P=0.016*	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

Males

DOSE	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3
Liver						
Hepatodiaphragmatic Nodule						
LESION RATES						
OVERALL (a)	1/10 (10%)	2/2 (100%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/10 (0%)
POLY-3 RATE (b)	1/10.00	2/2.00	1/1.00	0/0.00	1/1.00	0/10.00
POLY-3 PERCENT (g)	10%	100%	100%	0%	100%	0%
TERMINAL (d)	1/10 (10%)	2/2 (100%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	---	93 (T)	---
STATISTICAL TESTS						
POLY 3	(e)	P=0.005**	P=0.146	(e)	P=0.146	P=0.500N
POLY 1.5	(e)	P=0.005**	P=0.146	(e)	P=0.146	P=0.500N
POLY 6	(e)	P=0.005**	P=0.146	(e)	P=0.146	P=0.500N
COCH-ARM / FISHERS	P=0.096N	P=0.045*	P=0.182	(e)	P=0.182	P=0.500N
MAX-ISO-POLY-3	(e)	P<0.001**	P=0.022*	(e)	P=0.022*	P=0.158N

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Liver **Inflammation Granulomatous**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/2 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/2.00	0/1.00	0/0.00	0/1.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/2 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Lung **Inflammation Chronic**						
LESION RATES						
OVERALL (a)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	100%	90%	100%	100%	100%	100%
TERMINAL (d)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
POLY 1.5	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
POLY 6	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.488	P=0.500N	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.193	P=0.158N	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Lung: Alveolus **Infiltration Cellular Histiocyte**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	7/10 (70%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	7/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	70%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	7/10 (70%)	10/10 (100%)
FIRST INCIDENCE	---	---	---	---	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.002**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Goblet Cell Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Olfactory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	1/10 (10%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	1/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	10%	100%	100%	100%	100%	100%
TERMINAL (d)	1/10 (10%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.003**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Olfactory Epithelium Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Respiratory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Respiratory Epithelium Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Males					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Preputial Gland Inflammation Chronic						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	20%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.377	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Heart **Cardiomyopathy**						
LESION RATES						
OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	20%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	94 (T)	---	---	---	---	94 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.377	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Kidney **Nephropathy**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Larynx **Inflammation Chronic**						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Larynx **Metaplasia**						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Larynx: Squamous Epithelium Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	9/10 (90%)	7/10 (70%)	10/10 (100%)	9/10 (90%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	9/10.00	7/10.00	10/10.00	9/10.00	10/10.00
POLY-3 PERCENT (g)	0%	90%	70%	100%	90%	100%
TERMINAL (d)	0/10 (0%)	9/10 (90%)	7/10 (70%)	10/10 (100%)	9/10 (90%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P=0.002**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Liver **Hepatodiaphragmatic Nodule**						
LESION RATES						
OVERALL (a)	0/10 (0%)	4/4 (100%)	0/0 (0%)	3/3 (100%)	1/1 (100%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	4/4.00	0/0.00	3/3.00	1/1.00	1/10.00
POLY-3 PERCENT (g)	0%	100%	0%	100%	100%	10%
TERMINAL (d)	0/10 (0%)	4/4 (100%)	0/0 (0%)	3/3 (100%)	1/1 (100%)	1/10 (10%)
FIRST INCIDENCE	---	94 (T)	---	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	(e)	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
POLY 1.5	(e)	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
POLY 6	(e)	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
COCH-ARM / FISHERS	P=0.199N	P<0.001**	(e)	P=0.003**	P=0.091	P=0.500
MAX-ISO-POLY-3	(e)	P<0.001**	(e)	P<0.001**	P<0.001**	P=0.158

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Liver **Inflammation Granulomatous**						
LESION RATES						
OVERALL (a)	3/10 (30%)	0/4 (0%)	0/0 (0%)	0/3 (0%)	0/1 (0%)	6/10 (60%)
POLY-3 RATE (b)	3/10.00	0/4.00	0/0.00	0/3.00	0/1.00	6/10.00
POLY-3 PERCENT (g)	30%	0%	0%	0%	0%	60%
TERMINAL (d)	3/10 (30%)	0/4 (0%)	0/0 (0%)	0/3 (0%)	0/1 (0%)	6/10 (60%)
FIRST INCIDENCE	94 (T)	---	---	---	---	94 (T)
STATISTICAL TESTS						
POLY 3	(e)	P=0.307N	(e)	P=0.386N	P=0.689N	P=0.186
POLY 1.5	(e)	P=0.307N	(e)	P=0.386N	P=0.689N	P=0.186
POLY 6	(e)	P=0.307N	(e)	P=0.386N	P=0.689N	P=0.186
COCH-ARM / FISHERS	P=0.033*	P=0.330N	(e)	P=0.420N	P=0.727N	P=0.185
MAX-ISO-POLY-3	(e)	P=0.155N	(e)	P=0.199N	P=0.328N	P=0.089

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Lung **Inflammation Chronic**						
LESION RATES						
OVERALL (a)	10/10 (100%)	10/10 (100%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	10/10.00	10/10.00	10/10.00	9/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	100%	100%	100%	90%	100%	100%
TERMINAL (d)	10/10 (100%)	10/10 (100%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P=0.697	(e)	(e)	P=0.500N	(e)	(e)
POLY 1.5	P=0.697	(e)	(e)	P=0.500N	(e)	(e)
POLY 6	P=0.697	(e)	(e)	P=0.500N	(e)	(e)
COCH-ARM / FISHERS	P=0.699	(e)	(e)	P=0.500N	(e)	(e)
MAX-ISO-POLY-3	P=0.282N	(e)	(e)	P=0.158N	(e)	(e)

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Lung: Alveolus **Infiltration Cellular Histiocyte**						
LESION RATES						
OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	---	---	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Goblet Cell Hyperplasia						
LESION RATES						
OVERALL (a)	0/10 (0%)	8/10 (80%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	8/10.00	10/10.00	9/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	80%	100%	90%	100%	100%
TERMINAL (d)	0/10 (0%)	8/10 (80%)	10/10 (100%)	9/10 (90%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Olfactory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Olfactory Epithelium Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	90%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Respiratory Epithelium Accumulation, Hyaline Droplet						
LESION RATES						
OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Nose: Respiratory Epithelium Inflammation						
LESION RATES						
OVERALL (a)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	90%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)
TERMINAL SACRIFICE AT 14 WEEKS

	Females					
DOSE	**0 mg/m3**	**25 mg/m3**	**50 mg/m3**	**100 mg/m3**	**200 mg/m3**	**400 mg/m3**
Ovary Cyst						
LESION RATES						
OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)	0/10 (0%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	2/2.00	0/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	100%	0%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/2 (100%)	0/10 (0%)
FIRST INCIDENCE	94 (T)	---	---	---	94 (T)	---
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	P=0.053	P=0.227N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.053	P=0.227N
POLY 6	(e)	(e)	(e)	(e)	P=0.053	P=0.227N
COCH-ARM / FISHERS	P=0.192N	(e)	(e)	(e)	P=0.091	P=0.237N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	P=0.023*	P=0.066N

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are theP-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
(e)	Value of Statistic cannot be computed.
(g)	Poly-3 adjusted lifetime tumor incidence.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***